Table 4 Comparison of overall survival between patients with chemotherapy and no-chemotherapy in specific tumor grades, stages, nodal status and progesterone receptor status using a multivariate Cox proportional hazard model
Variables | Overall Survival | ||
|---|---|---|---|
Events | Hazard Ratio (95% Confidence Interval) | P a | |
N0 (n = 961) | 613 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.790 (0.555–1.125) | 0.192 |
N+ (n = 544) | 373 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.734 (0.566–0.951) | 0.019 |
Grade Well/Moderately n = 940) | 579 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.788 (0.581–1.068) | 0.124 |
Grade Poorly/undifferentiated n = 524) | 382 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.628 (0.460–0.859) | 0.004 |
Stage I n = 561) | 351 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.644 (0.384–1.081) | 0.096 |
Stage II n = 673) | 429 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.628 (0.456–0.866) | 0.004 |
Stage III n = 283) | 218 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.696 (0.504–0.963) | 0.029 |
PR + Stage I n = 424) | 230 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.603 (0.312–1.167) | 0.133 |
PR + Stage II n = 523) | 302 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.783 (0.538–1.140) | 0.202 |
PR + Stage III n = 192) | 132 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.571 (0.372–0.875) | 0.010 |
PR- Stage I n = 40) | 31 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 1.205 (0.304–4.777) | 0.791 |
PR- Stage II n = 55) | 40 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.201 (0.051–0.792) | 0.022 |
PR- Stage III n = 30) | 25 |  |  |
No-chemotherapy | Â | Reference | Â |
Chemotherapy |  | 0.242 (0.060–0.972) | 0.046 |